<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: This retrospective analysis assessed safety and tolerability of vildagliptin (Vilda) as an add-on to <z:chebi fb="0" ids="6801">metformin</z:chebi> in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) patients with <z:mpath ids='MPATH_458'>normal</z:mpath> renal function (GFR &gt;80mL/min/1.73m(2)) and mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> (GFR: &gt;50 to ≤80mL/min/1.73m(2)) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Adverse events (AE) from this 12-week, randomized, open-label study comparing Vilda 100mg and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZD) as an add-on therapy in patients with T2DM inadequately controlled (HbA(1c): 7-10%) on a stable dose of <z:chebi fb="0" ids="6801">metformin</z:chebi> (≥1000mg/day) were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Of 2627 randomized patients, 1278 in the Vilda and 635 in the TZD groups had <z:mpath ids='MPATH_458'>normal</z:mpath> renal function; 463 in the Vilda and 230 in the TZD groups had mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Higher incidence of <z:hpo ids='HP_0002315'>headache</z:hpo> and <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> was noted in both Vilda groups, whereas those with mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> receiving TZD experienced a higher incidence of peripheral <z:hpo ids='HP_0000969'>edema</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">URI</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Fewer patients in the Vilda group discontinued the study due to AEs compared to TZD group </plain></SENT>
<SENT sid="5" pm="."><plain>Serious AEs were greater in TZD groups (<z:mpath ids='MPATH_458'>normal</z:mpath>: 2.4%; mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>: 3.0%) compared to Vilda groups (<z:mpath ids='MPATH_458'>normal</z:mpath>: 1.6%; mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e>: 2.4%) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The safety profile of Vilda or TZD as an add-on to <z:chebi fb="0" ids="6801">metformin</z:chebi> was similar in patients with mild <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> renal function </plain></SENT>
</text></document>